Page 126 - 2019_06-Haematologica-web

J.F. Seymour et al.
analysis also adds to the weight of data supporting the use of POD24 rate as an efficacy end point for future clinical trials in patients with previously untreated FL.
Acknowledgments
The authors would like to thank all of the patients who
participated in the GALLIUM study, and acknowledge all of the study investigators and their staff as well as the GALLIUM study team. Third-party medical writing assistance, under the direction of John Seymour, was provided by Roger Nutter, Scott Malkin and Helen Cathro of Gardiner-Caldwell Communications, and was funded by F. Hoffmann-La Roche Ltd.
References
1. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105(4):1417-1423.
2. Press OW, Unger JM, Rimsza LM, et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tosi- tumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol. 2013;31(3):314-320.
3. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, ran- domised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203-1210.
4. Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after ritux- imab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516-2522.
5. Casulo C, Le-Rademacher J, Dixon J, et al. Validation of POD24 as a robust early clini- cal endpoint of poor survival in follicular lymphoma: results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) investigation using individual data from 5,453 patients on 13
clinical trials. Blood. 2017;130(Suppl 1):412. 6. Herter S, Herting F, Mindigl O, et al. Preclinical activity of the type II CD20 anti- body GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther.
2013;12(10):2031-2042.
7. Mössner E, Brünker P, Moser S, et al.
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B- cell cytotoxicity. Blood. 2010; 115(22):4393- 4402.
8. Hiddemann W, Barbui AM, Canales MA, et al. Immunochemotherapy with obinu- tuzumab or rituximab for previously untreated follicular lymphoma in the GAL- LUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018; 36(23):2395-2404.
9. Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331-1344.
10. Jurinovic V, Kridel R, Staiger AM, et al. Clinicogenetic risk models predict early pro- gression of follicular lymphoma after first- line immunochemotherapy. Blood. 2016;128(8):1112-1120.
11. Maurer MJ, Bachy E, Ghesquières H, et al. Early event status informs subsequent out- come in newly diagnosed follicular lym- phoma. Am J Hematol. 2016;91(11):1096- 1101.
12.
13.
14.
15.
16.
17.
Montoto S, Lopez-Guillermo A, Ferrer A, et al. Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. Ann Oncol. 2002;13(4):525-530. Murakami S, Kato H, Yamamoto K, et al. Combination of high serum lactate dehy- drogenase levels at the time of first diagnosis and progression predicts early lymphoma related death in patients with follicular lym- phoma receiving R-CHOP regimen. Blood. 2014;124(21):2972.
Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prog- nostication for patients receiving first-line immunochemotherapy for follicular lym- phoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16(9):1111-1122.
Huet S, Tesson B, Jais JP, et al. A gene- expression profiling score for prediction of outcome in patients with follicular lym- phoma: a retrospective training and valida- tion analysis in three international cohorts. Lancet Oncol. 2018;19(4):549-561.
O’Shea D, O’Riain C, Taylor C, et al. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall sur- vival. Blood. 2008;112(8):3126-3129.
Kridel R, Chan FC, Mottok A, et al. Histological transformation and progression in follicular lymphoma: a clonal evolution study. PLoS Med. 2016;13(12):e1002197.
1208
haematologica | 2019; 104(6)